QGO Finance: Allots ₹1 Crore in Non-Convertible Debentures

QGO Finance Limited has announced the allotment of 100 Unsecured, Unlisted, Redeemable Non-Convertible Debentures (NCDs) worth ₹1,00,00,000 (Rupees One Crore). The NCDs, each valued at ₹1,00,000, were issued on October 30, 2026, with a tenure of 9 years, maturing on October 29, 2035. This issuance is part of the company’s ongoing financing activities.

Financing Activity: NCD Allotment

QGO Finance Limited has completed the allotment of Non-Convertible Debentures (NCDs), a key financing instrument for the company. A resolution passed by the majority of the Board of Directors confirmed the issuance of 100 NCDs, each with a face value of ₹1,00,000. This brings the total value of the allotment to ₹1,00,00,000, equivalent to Rupees One Crore.

Details of the NCD Issuance

The allotted securities are classified as Transferable, Unsecured, Unlisted, and Redeemable Non-Convertible Debentures. The issuance was conducted on a Private Placement basis. The allotment date was confirmed as October 30, 2026, with a maturity date set for October 29, 2035, providing a tenure of 9 years. The interest rate offered on these NCDs is 12% per annum, with interest and principal payments scheduled on a monthly basis.

Key Features of the Debentures

  • Type of Securities: Unsecured, Unlisted, Redeemable Non-Convertible Debentures (NCDs)
  • Type of Issuance: Private Placement Basis
  • Total Securities Allotted: 100
  • Size of Allotment: Rs. 1,00,00,000/- (Rupees One Crore Only)
  • Tenure: 9 Years (Allotment: 30.10.2026, Maturity: 29.10.2035)
  • Coupon/Interest Rate: 12% per annum, payable monthly

The debentures are unsecured, meaning no specific assets have been pledged as collateral. Consequently, there are no charges or securities created over the company’s assets in relation to this issuance. The company has also confirmed that there are no special rights or privileges attached to these instruments, and no delays in interest or principal payments have occurred.

Source: BSE

Previous Article

MTAR Technologies: Investor Presentation October 2026 Outlines Growth Strategy

Next Article

Sun Pharma: ILUMYA® Approved in U.S. for Psoriatic Arthritis Treatment